A multi-national, multi-center, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of Laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)
Aims: To assess the efficacy, safety and tolerability of a daily dose of 0.6 mg and 1.2 mg of Laquinimod as compared to placebo in subjects with RRMS.
Principal Investigator: Afif Hentati, MD
IRB Approval Number: EH12-294
Funding Source: TEVA Pharmaceuticals
Contact: Please call 847.570.1439 with any questions regarding the study.
Open To Enrollment: Yes

ASSESS: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg doses administered orally once daily or glatiramer acetate administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
Aims: The purpose of this study is to compare 2 doses of fingolimod to copaxone and to evaluate the efficacy and safety of fingolimod 0.25mg
Principal Investigator: Afif Hentati, MD
IRB Approval Number: EH12-289
Funding Source: Novartis
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Aim: To assess patient reported outcomes for safety and quality of life issues for patients taking Tecfidera
Principal Investigator: Susan Rubin, MD
IRB Approval Number: EH13-416
Funding Source: Biogen, Idec.
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes

× Alternate Text